Clinical profile of Spanish hepatitis C virus-infected treatment-naïve patients with compensated cirrhosis in the CREST study.

Francisco JorqueraFrancisco LedesmaAdriana AhumadaMaría Luisa ManzanoAgustín CastiellaSara LorenteMireia MiquelZoe MariñoJosé CastelloteEva SanzJuan Uriz

Published in: Gastroenterologia y hepatologia (2024)

Treatment with glecaprevir/pibrentasvir for 8 weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitis C among those patients still to be diagnosed and treated in Spain.

Keyphrases

hepatitis c virus
end stage renal disease
newly diagnosed
chronic kidney disease
healthcare
replacement therapy
patient reported outcomes
health information
gestational age